Expertise in
2
conditions

Dr. David A. Smith

Oncology
Northwest Cancer Specialists PC
210 SE 136th Ave, 
Vancouver, WA 
Expertise in
2
conditions
Northwest Cancer Specialists PC
210 SE 136th Ave, 
Vancouver, WA 

Overview

David Smith is an Oncologist practicing medicine in Vancouver, Washington.

Dr. Smith is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Follicular Lymphoma, Pancreatoblastoma, and Lung Cancer.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Northwest Cancer Specialists PC
210 SE 136th Ave, Vancouver, WA 98684

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Enrollment Status: Terminated
Publish Date: June 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

5 Total Publications

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: August 17, 2020
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
 (7.4 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brendan Curti is an Oncologist practicing medicine in Portland, Oregon. Dr. Curti is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Melanoma, Renal Cell Carcinoma (RCC), Prostate Cancer, and Metastatic Uveal Melanoma. Dr. Curti is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
 (7.4 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachel Sanborn is an Oncologist practicing medicine in Portland, Oregon. Dr. Sanborn is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration. Dr. Sanborn is currently accepting new patients.

Expertise in
7
conditions
Expertise in
7
conditions
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (11.2 miles away)
503-494-5596
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Druker is an Oncologist practicing medicine in Portland, Oregon. Dr. Druker is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), and Philadelphia-Negative Chronic Myeloid Leukemia. Dr. Druker is currently accepting new patients.

Frequently Asked Questions about Dr. David A. Smith

How do I make an appointment with Dr. David A. Smith?

You can book an appointment with Dr. David A. Smith by calling their office at 360-573-0471. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David A. Smith a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David A. Smith is classified as an Advanced expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David A. Smith specialize in?

While Dr. David A. Smith is a Oncology, they have specific expertise in Pleuropulmonary Blastoma, Follicular Lymphoma, and Pancreatoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. David A. Smith participate in research or clinical trials?

Yes. Dr. David A. Smith has published 5 articles and abstracts on conditions like Pleuropulmonary Blastoma. You can view a list of Dr. David A. Smith's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Smith's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile